isopropyl 4-(6-(2,4-dimethyl-6-(methylsulfonyl)pyridin-3-ylamino)-5-methoxypyrimidin-4-yloxy)piperidine-1-carboxylate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: isopropyl 4-(6-(2,4-dimethyl-6-(methylsulfonyl)pyridin-3-ylamino)-5-methoxypyrimidin-4-yloxy)piperidine-1-carboxylate
• 英文别名: Isopropyl 4-(6-(2,4-dimethyl-6-(methylsulfonyl)pyridin-3-ylamino)-5-methoxypyrimidin-4-yloxy)piperidine-1-carboxy-late；propan-2-yl 4-[6-[(2,4-dimethyl-6-methylsulfonylpyridin-3-yl)amino]-5-methoxypyrimidin-4-yl]oxypiperidine-1-carboxylate
• 化学式: C₂₂H₃₁N₅O₆S
• 分子量: 493.584
• InChiKey: PLDNGZQJBABRGF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  34
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  141
• 氢给体数：
  1
• 氢受体数：
  10

反应信息

• 作为产物：
  描述：

  isopropyl 4-(6-(6-bromo-2,4-dimethylpyridin-3-ylamino)-5-methoxypyrimidin-4-yloxy)piperidine-1-carboxylate 、 sodium methansulfinate 在 copper(I) trifluoromethanesulfonate benzene N,N'-二甲基乙二胺 作用下， 以 二甲基亚砜 为溶剂， 反应 8.0h， 生成 isopropyl 4-(6-(2,4-dimethyl-6-(methylsulfonyl)pyridin-3-ylamino)-5-methoxypyrimidin-4-yloxy)piperidine-1-carboxylate
  参考文献：
  名称：

  Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto

  摘要：

  本发明涉及某些取代的吡啶基和嘧啶基衍生物，其化学式为（Ia），这些衍生物是代谢调节剂。因此，本发明的化合物在治疗与代谢相关的疾病和并发症方面非常有用，如糖尿病和肥胖症。

  公开号：

  US20060155128A1

文献信息

• PROCESS FOR THE PREPARATION OF TRI-SUBSTITUTED PYRIDINE AND TRI-SUBSTITUTED PYRIMIDINE DERIVATIVES USEFUL AS GDIR AGONISTS
  申请人：Choudhury Anusuya

  公开号：US20100113479A1

  公开（公告）日：2010-05-06

  The present invention is directed to novel processes for the preparation of tri-substituted pyridine and tri-substituted pyrimidine derivatives, useful as glucose dependent insulinotropic receptor agonist, for the treatment of metabolic-related disorders and complications thereof, such as, diabetes and obesity.

  本发明涉及一种制备三取代吡啶和三取代嘧啶衍生物的新型方法，其作为葡萄糖依赖性胰岛素促进受体激动剂，用于治疗代谢相关疾病及其并发症，例如糖尿病和肥胖症。
• Substituted pyrindinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
  申请人：Jones M. Robert

  公开号：US20070078150A1

  公开（公告）日：2007-04-05

  The present invention relates to certain substituted pyridinyl and pyrimidinyl derivatives of Fomula (Ia) that are modulators of metabolism. Accordingly, compounds of the present invention are useful in the treatment of metabolic-related disorders and complications thereof, such as, diabetes and obesity.

  本发明涉及某些取代的吡啶基和嘧啶基衍生物，其化学式为(Ia)，它们是代谢调节剂。因此，本发明的化合物在代谢相关疾病及其并发症的治疗中是有用的，例如糖尿病和肥胖症。
• Use of GPR119 receptor agonists for increasing bone mass and for treating osteoporosis, as well as combination therapy relating thereto
  申请人：Arena Pharmaceuticals, Inc.

  公开号：EP2253311A2

  公开（公告）日：2010-11-24

  The present invention relates to the use of GPR119 receptor agonists for treating or preventing a condition characterized by low bone mass, such as osteoporosis, and for increasing bone mass in an individual. The present invention further relates to the use of a GPR119 receptor agonist in combination with a dipeptidyl peptidase IV (DPP-IV) inhibitor for treating or preventing a condition characterized by low bone mass, such as osteoporosis, and for increasing bone mass in an individual. A GPR119 receptor agonist and the combination of a GPR119 receptor agonist and a DPP-IV inhibitor promote bone formation in an individual.

  本发明涉及 GPR119 受体激动剂用于治疗或预防以低骨量为特征的疾病，如骨质疏松症，以及用于增加个体的骨量。本发明进一步涉及 GPR119 受体激动剂与二肽基肽酶 IV (DPP-IV) 抑制剂联合用于治疗或预防以低骨量为特征的疾病，如骨质疏松症，以及增加个体的骨量。GPR119 受体激动剂以及 GPR119 受体激动剂与 DPP-IV 抑制剂的组合可促进个体的骨形成。
• SUBSTITUTED PYRIDINYL AND PYRIMIDINYL DERIVATIVES AS MODULATORS OF METABOLISM AND THE TREATMENT OF DISORDERS RELATED THERETO
  申请人：Arena Pharmaceuticals, Inc.

  公开号：EP1732562B1

  公开（公告）日：2007-12-19
• USE OF GPR119 RECEPTOR AGONISTS FOR INCREASING BONE MASS AND FOR TREATING OSTEOPOROSIS, AS WELL AS COMBINATION THERAPY RELATING THERETO
  申请人：Arena Pharmaceuticals, Inc.

  公开号：EP2004157B1

  公开（公告）日：2011-01-12